A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Overview of attention for article published in BMC Pulmonary Medicine, January 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy: 1 policy source

twitter: 8 X users

Readers on

mendeley: 116 Mendeley

Summary Policy documents X

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 312,395 followers.

More trials in LAMA grp SHINE study: https://t.co/0XTcZJ0rFK SPARK trial: https://t.co/ZFCcpSWL8S GLOW5: https://t.co/aPe5usEnBP #ADIR15

Reply Repost Favourite

@sianmidwinter https://t.co/XsLxGM85xU

Reply Repost Favourite

A blinded evaluation of the efficacy and safety of glycopyrronium versus tiotropium, in patients with COPD http://t.co/mmwWvF6Nu5

Reply Repost Favourite

Will new agents just rely on non-inferiority trials? - glycopyrronium versus tiotropium #COPD http://t.co/cXwPLbGteY

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.